Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Lymphoma

Leukemia

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Leukemia, Lymphoid

Lymphoma, B-Cell

Neoplasms by Histologic Type

Hematologic Diseases

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphosarcoma

Acute Lymphoblastic Leukemia

Lymphoblastic Lymphoma

B-cell Lymphoma

Acute Graft Versus Host Disease

CD19 CAR T cells transduced with a lentiviral vector to express anti-CD19 scFv CD3z:CD28 administered by IV infusion.

CD19 CAR T cells transduced with a lentiviral vector to express anti-CD19 scFv CD3z:CD28 administered by IV infusion. Subjects will receive 0.1-10 x 10\^6 transduced CAR T cells as a split dose over three days as follows:Day 1, 10% fraction, Day 2, 30% fraction, Day 3, 60% fraction.

CD19 CAR T

Ligen Liu

This is a single center, single arm, open-label phase 1 study to determine the safety and efficacy of autologous T cells expressing CD19 chimeric antigen receptors in adults with CD19+ B cell malignancies.

This is a single-center, Open Label phase I clinical trial, 9 subjects planned to be enrolled. The subjects will be divided into low-dose group, medium-dose group and high-dose group.Dose CAR+ cells/kg Low 1×105 Medium 2×106 High 6×106

CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies

CD19-targeting CAR T Cell Therapy in the Treatment of Relapsed or Refractory CD19 Positive B-cell Malignancies

To assess the frequency and severity of toxicities and adverse events according to NCI CTC v4.0

To assess the overall response rate after CD19 CAR T infusion in R/R B cell malignancies

To assess the overall survival in patients with R/R B cell malignancies

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies	NCT03559439	B-cell Malignan... B-cell Lymphoma B-Cell Acute Ly...	CD19 CAR T	18 Years - 75 Years	Shanghai Tong Ren Hospital
CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies	NCT03559439	B-cell Malignan... B-cell Lymphoma B-Cell Acute Ly...	CD19 CAR T	18 Years - 75 Years	Shanghai Tong Ren Hospital

Spots Global Cancer Trial Database for cd19 car t

Every month we try and update this database with for cd19 car t cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for cd19 car t

Every month we try and update this database with for cd19 car t cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for cd19 car t cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.